Halozyme Therapeutics, Inc. (HALO)
68.87
+0.46
(+0.67%)
USD |
NASDAQ |
Dec 26, 16:00
68.87
0.00 (0.00%)
After-Hours: 04:51
Halozyme Therapeutics Shareholders Equity (Quarterly): 503.92M for Sept. 30, 2025
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Johnson & Johnson | 79.28B |
| Merck & Co., Inc. | 51.85B |
| AIM ImmunoTech, Inc. | -6.077M |
| Bristol Myers Squibb Co. | 18.55B |
| Protalix Biotherapeutics, Inc. | 52.91M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.221B |
| Total Liabilities (Quarterly) | 1.717B |
| Debt to Equity Ratio | 2.998 |
| Current Ratio | 1.587 |
| Net Debt Paydown Yield | -0.02% |